Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
90 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Thromboembolism - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Thromboembolism - Pipeline Review, H1 2015', provides an overview of the Thromboembolism's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thromboembolism and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Thromboembolism - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Thromboembolism and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Thromboembolism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Thromboembolism pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Thromboembolism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Thromboembolism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Thromboembolism Overview 8 Therapeutics Development 9 Pipeline Products for Thromboembolism - Overview 9 Pipeline Products for Thromboembolism - Comparative Analysis 10 Thromboembolism - Therapeutics under Development by Companies 11 Thromboembolism - Therapeutics under Investigation by Universities/Institutes 13 Thromboembolism - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Thromboembolism - Products under Development by Companies 17 Thromboembolism - Products under Investigation by Universities/Institutes 18 Thromboembolism - Companies Involved in Therapeutics Development 19 Bayer AG 19 Cereno Scientific AB 20 CSL Limited 21 Daiichi Sankyo Company, Limited 22 Gamma Therapeutics, Inc. 23 Green Cross Corporation 24 Isis Pharmaceuticals, Inc. 25 Portola Pharmaceuticals, Inc. 26 Regado Biosciences, Inc. 27 Sanofi 28 Thromboembolism - Therapeutics Assessment 29 Assessment by Monotherapy Products 29 Assessment by Target 30 Assessment by Mechanism of Action 32 Assessment by Route of Administration 34 Assessment by Molecule Type 36 Drug Profiles 38 betrixaban - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 C-3 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 CSL-3F7 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 edoxaban tosylate - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Gammarin - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 GCC-2107 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 ISIS-FXIRx - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Lysimab - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Protein for Thromboembolism and Blood Coagulation - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 REG-2 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 rivaroxaban - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 semuloparin - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Small Molecules to Inhibit HDAC for Thromboembolism - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 TAP-ANV - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 YG-001 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Thromboembolism - Recent Pipeline Updates 61 Thromboembolism - Dormant Projects 78 Thromboembolism - Discontinued Products 79 Thromboembolism - Product Development Milestones 80 Featured News & Press Releases 80 Dec 08, 2014: Daiichi Sankyo Launches New Formulation of LIXIANA 60 mg Tablets (edoxaban) in Japan 80 Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 80 Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting 82 Oct 28, 2014: U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo's Once-Daily SAVAYSA for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation 82 Sep 26, 2014: Daiichi Sankyo Receives Approval for Additional Indications of LIXIANA (edoxaban) in Japan 83 Aug 30, 2014: Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Patients with Venous Thromboembolism (VTE) 83 Jun 23, 2014: Regado Biosciences REG2 Demonstrates Dose and Concentration Dependent Suppression of Thrombin Generation 84 May 28, 2014: Xarelto from Bayer Submitted in Japan for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism as well as for the Prevention of Recurrent Venous Thromboembolism 85 May 22, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 86 May 12, 2014: Portola Pharmaceuticals Begins Enrollment in Phase 3 Study of FDA-Designated Breakthrough Therapy Andexanet Alfa and Factor Xa Inhibitor XARELTO 87 Appendix 89 Methodology 89 Coverage 89 Secondary Research 89 Primary Research 89 Expert Panel Validation 89 Contact Us 90 Disclaimer 90
List of Tables Number of Products under Development for Thromboembolism, H1 2015 9 Number of Products under Development for Thromboembolism - Comparative Analysis, H1 2015 10 Number of Products under Development by Companies, H1 2015 12 Number of Products under Investigation by Universities/Institutes, H1 2015 13 Comparative Analysis by Late Stage Development, H1 2015 14 Comparative Analysis by Clinical Stage Development, H1 2015 15 Comparative Analysis by Early Stage Development, H1 2015 16 Products under Development by Companies, H1 2015 17 Products under Investigation by Universities/Institutes, H1 2015 18 Thromboembolism - Pipeline by Bayer AG, H1 2015 19 Thromboembolism - Pipeline by Cereno Scientific AB, H1 2015 20 Thromboembolism - Pipeline by CSL Limited, H1 2015 21 Thromboembolism - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 22 Thromboembolism - Pipeline by Gamma Therapeutics, Inc., H1 2015 23 Thromboembolism - Pipeline by Green Cross Corporation, H1 2015 24 Thromboembolism - Pipeline by Isis Pharmaceuticals, Inc., H1 2015 25 Thromboembolism - Pipeline by Portola Pharmaceuticals, Inc., H1 2015 26 Thromboembolism - Pipeline by Regado Biosciences, Inc., H1 2015 27 Thromboembolism - Pipeline by Sanofi, H1 2015 28 Assessment by Monotherapy Products, H1 2015 29 Number of Products by Stage and Target, H1 2015 31 Number of Products by Stage and Mechanism of Action, H1 2015 33 Number of Products by Stage and Route of Administration, H1 2015 35 Number of Products by Stage and Molecule Type, H1 2015 37 Thromboembolism Therapeutics - Recent Pipeline Updates, H1 2015 61 Thromboembolism - Dormant Projects, H1 2015 78 Thromboembolism - Discontinued Products, H1 2015 79
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
